Federated Hermes Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Key Points

• Federated Hermes Inc. increased its stake in Keros Therapeutics by 882.3% in Q1, owning over 1.2 million shares worth approximately $12.5 million.
• Multiple analysts have lowered price targets for Keros Therapeutics, with Bank of America reducing its target from $32 to $18, indicating a shift in market sentiment.
• Keros Therapeutics reported earnings of $3.62 per share for the last quarter, significantly exceeding the consensus estimate of ($0.01), highlighting strong revenue performance.

Federated Hermes Inc. raised its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 882.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,224,139 shares of the company's stock after buying an additional 1,099,519 shares during the quarter. Federated Hermes Inc. owned about 3.01% of Keros Therapeutics worth $12,474,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of KROS. Vanguard Group Inc. boosted its position in shares of Keros Therapeutics by 5.4% during the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock valued at $30,981,000 after acquiring an additional 100,691 shares during the last quarter. Braidwell LP boosted its position in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after acquiring an additional 1,187,199 shares during the last quarter. Darwin Global Management Ltd. boosted its position in shares of Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after acquiring an additional 163,403 shares during the last quarter. Millennium Management LLC boosted its position in shares of Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after acquiring an additional 305,169 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Keros Therapeutics by 5.5% during the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after acquiring an additional 39,815 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Analysts Set New Price Targets

KROS has been the topic of several recent research reports. Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Scotiabank decreased their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Wedbush reaffirmed a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Truist Financial decreased their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $30.56.

Keros Therapeutics Stock Performance

Shares of KROS opened at $14.32 on Friday. The stock has a market capitalization of $581.68 million, a PE ratio of -79.56, a P/E/G ratio of 2.59 and a beta of 1.33. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The company's 50-day simple moving average is $14.05 and its 200-day simple moving average is $12.67.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. During the same quarter in the prior year, the company earned ($1.21) earnings per share. On average, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.